To conclude, this study supports the contention that TYMS expression (at the mRNA level), dMMR and CIMP-High status are clinically relevant markers in patients with sporadic stage II colon cancer being considered for fluoropyrimidine-based adjuvant therapy. Here, TYMS is linked to colonic neoplasm.